The prevalence of hepatitis A virus (HAV) protective antibody in 98 Thai HIV-infected children who achieved immune recovery after antiretroviral therapy was 12.2%. After a 2-dose HAV vaccination, 98.8%
land) as reported only from those pediatricians who vaccinate in their clinics are shown (vaccine specific data are provided in Table, Supplemental Digital Content 1, http://links.lww.com/INF/A608). Regarding all vaccines, except of inactivated polio vaccine, there are significant differences between the countries. As compared with all other 5 countries, the refusal rate for Hepatitis B was significantly higher in France.
In all, 64% of respondents did not think that parents who refuse some vaccines should switch to another pediatrician, while 9% endorsed this option. However, in cases of total refusal, 27% thought that parents should switch to another pediatrician. Only 12% of respondents thought that any form of vaccination refusal is always causing a disturbance to the physician-family relationship.
Finally, 69% of responding pediatricians preferred a shared decision-making approach to handle refusing parents, whereas 17% thought an authoritarian approach is more appropriate.
DISCUSSION
Our study shows that the magnitude of total parental refusal to all vaccines, as estimated by primary care pediatricians in Europe is negligible. To our knowledge, this is the first multinational evidence generated in Europe regarding vaccination refusal. Physicians who actually vaccinate in their practices gave an even lower figure for total refusal rate than pediatricians who only discuss vaccination issues with parents. In a recent survey, vaccinations are administered at the pediatrician's office in 8 of 31 European countries, in the healthcare center in 9, and in multiple locations in 12 countries. 8 This heterogeneity in vaccination settings across Europe can explain the different estimations. Our figures are similar to the most recent 2008 US National Immunization Survey assessment of 0.6% of children 19 to 35 months of age receiving no vaccinations. 9 In our study, the frequency of partial refusal or alternative vaccination schedules was estimated by 38% of pediatricians as 1% to 5%. Partial refusal and alternative vaccination schedules result in under-vaccination, with the possible consequence of exposure of the under-vaccinated children to disease breakouts.
In the subgroup analysis, we have shown significant differences between refusal rates for specific vaccines in different countries. There seems to be a correlation between the high refusal rates for Hepatitis B in France possibly related to the 1997 report of central nervous system demyelination associated with that vaccine, 10 and the very low coverage rate for that vaccine in France (30% in 2007) compared with all other European countries (90%-97% in 2007). 11 However, it is difficult to explain differences between countries regarding other vaccines refusal rates found in our study.
According to the survey respondents, similar to the United States, 1 the top reason for vaccine refusal or alternative schedules is parental fear of adverse events. Our study also highlights the belief in alternative medicine as a factor related to vaccine refusal. In a survey of parents of school aged children in 4 US states in 2003, parents of exempt children were more likely than parents of vaccinated children to have providers who offered complementary or alternative health care. 5 The majority of our responding pediatricians prefer a shared decision-making approach when facing refusing parents. Only 9% endorsed the option of discontinuing care. However, 27% would favor this approach toward parents who refuse all vaccines. These results are different from a similar survey done in 2005 among a national sample of US pediatricians in which 28% and 39% would dismiss a family for refusing selected vaccines and all vaccines, respectively. 3 The relatively lower number of European pediatricians who are in favor of dismissing family refusing vaccines is in accordance with the American Academy of Pediatrics policy statement published in 2005, suggesting to address refusal by respectfully listening to parental concerns, explaining the risk of nonimmunization, and discussing the specific vaccines that are of most concern to parents. 4 Our study has 2 limitations. First, the estimates of refusal were based on pediatricians' perception and not on patients' health records. In comparison, the National Immunization Survey in the United States is based on both parents' telephone interviews and providers' verification of data through the patients' immunization records. Second, there is a wide inter country variation in the number of responding pediatricians. Despite this heterogeneity, we assume that the phenomenon of parental vaccination refusal is influenced more by socioeconomic status, moral and philosophic trends, and less by the country of residence or the nature of the local health care system.
Following this study, The EAPRASnet infrastructure might facilitate intervention studies aiming at further improving vaccination rates. Moreover, HIV-infected patients have a higher incidence of liver disease from hepatotrophic viruses and adverse effects of antiretroviral drugs.
2,3 Thus, HIV-infected persons benefit from immunization against HAV.
The inactivated HAV vaccine is safe and highly immunogenic in HIV-seronegative individuals. HIV-infected patients are recommended to receive 2 doses of HAV vaccination according to the Advisory Committee on Immunization Practices (ACIP) recommendations. 4 However, in Thailand, HAV vaccination is not part of a national compulsory immunization program. HIV infection impairs antibody responses to infectious agents as well as vaccines. [5] [6] [7] However, recent studies during the antiretroviral therapy (ART) era show that HAV vaccine is immunogenic and safe in HIV-infected individuals, although a suboptimal antibody response may be achieved. 7, 8 The objectives of our study were (1) to determine the prevalence of HAV protective antibody in Thai HIV-infected children with immune recovery after ART and (2) to assess the immunogenicity and safety of HAV vaccine administered to these children.
PATIENTS AND METHODS
The study had a 2-step design. The first step was a crosssectional study to determine the proportion of HIV-infected children who had HAV protective antibody. Children who had no HAV protective antibody received 2 doses of HAV vaccine in the second step. The study was conducted at Chiang Mai University Hospital, Thailand, from February to October 2009. Eligibility criteria included having (1) severe immunosuppression (nadir CD4 lymphocyte percentage Ͻ15 or CD4 lymphocyte count Ͻ200 cells/L) 9 and (2) evidence of immune recovery, defined as CD4 lymphocyte percentage Ն15 or CD4 lymphocyte count Ն200 cells/L for at least 3 months after receiving ART. Exclusion criteria were having (1) a history of HAV vaccination or HAV disease, (2) received immunosuppressive agents within 3 months, or (3) received blood component transfusion within 6 months before the study.
Blood samples were obtained at enrollment to measure HAV antibody level in all children. Children who had no HAV protective antibody, defined as anti-HAV antibody Ͻ20 mIU/mL, were given 2 intramuscular 0.5 mL doses of 720 ELISA (enzymelinked immunosorbent assay) units of inactivated HAV vaccine, HAVRIX (GlaxoSmithKline, Rixensart, Belgium) 6 months apart.
They had blood drawn at 1 month after each dose of the vaccine to measure the anti-HAV antibody level. Vaccine safety and tolerability were monitored by the use of a 72-hour report card given to guardians.
Anti-HAV antibody level was measured by Vitek Immunodiagnostic Assay System (VIDAS, bioMérieux SA, Marcy l'Etoile, France). All specimens were tested in one single batch. Anti-HAV antibody titers of Ն20 mIU/mL were considered to be protective against HAV infection and also defined as HAV seropositive. The antibody responses were further classified as "low" if titers Ͻ250 mIU/mL and "high" if titers were Ն250 mIU/mL. 10 Statistical analyses were performed using the Statistical Package for Social Science version 11.5 software (SPSS Inc., Chicago, IL). Continuous variables were compared by Student t test. Categorical variables were compared by 2 or Fisher exact test, as appropriate. A P value of Ͻ0.05 was considered to be significant for 2-sided tests. Multivariate logistic regression analyses were also conducted to determine independent predictors of the vaccine response. Variables entry into analyses were based on the P values of the univariate tests being Ͻ0.20.
RESULTS
Ninety-nine children were enrolled. Ninety-eight subjects completed the study. One subject who was HAV-seronegative at enrollment dropped out after the first dose of vaccine and was excluded from the analyses. There were 47 (48%) males. The mean age was 12. Of the 98 children, 12 (12.2%) had HAV protective antibody at enrollment. Clinical and demographic characteristics of the children with and without protective antibody were compared to identify factors associated with the presence of HAV protective antibody at enrollment. No significant difference in any characteristic was found between the 2 groups (data not shown).
Of the 86 children who were given HAV vaccine, 59 (68.6%) seroconverted after the first dose with geometric mean antibody titers (GMTs) of 46.02 mIU/mL. After 2 doses, 85 children (98.8%) seroconverted with GMTs of 520.95 mIU/mL. Only 1 child did not respond to 2 doses of the vaccine. His CD4 lymphocyte count and plasma HIV RNA level at enrollment were 885 cells/L and Ͻ50 copies/mL, respectively. Among the 85 who responded, 56 (65.9%) had high anti-HAV and 29 (34.1%) had low anti-HAV response. Clinical characteristics of the 2 groups are shown in Table 1 . Factors that were more common in children with high antibody response were younger age (P ϭ 0.03), higher CD4 lymphocyte count, and lower plasma HIV RNA level at enrollment (P ϭ 0.02 and 0.04, respectively). By multivariate logistic regression analyses, female gender (adjusted odds ratio ͓AOR͔ 4.1; 95% CI: 1.3-12.5), age Ͻ12 years (AOR: 6.1; 95% CI: 1.7-22.0), and CD4 cell count at enrollment Ն500 cells/L (AOR: 4.5; 95% CI: 1.1-18.8) were the significant factors associated with high HAV antibody levels.
Pain at the injection site was the only reported adverse reaction. It had been reported in 7 participants (7.1%), all after the
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Hepatitis A Vaccine and HIV first vaccine dose. The pain was mild and resolved spontaneously within 1 to 3 days.
DISCUSSION
The prevalence of HAV infection in our HIV-infected children is 12.2%, which is similar to the 11.6% found in healthy Thai children aged 8 to 15 years. 11 Almost all of HIV-infected children with immune recovery after ART developed protective antibody after a standard 2-dose HAV vaccination. However, we found that the response rate after the first dose of the vaccine was only 68.6%, compared with the rate of nearly 100% in healthy children. 12 Thus, our study supports the ACIP recommendation that HIV-infected children receive 2 doses of HAV vaccine. The vaccine response rates in HIV-infected children who had had immune recovery from ART varied from 84.5% to 100%. 10, 13, 14 In 1 study from Brazil, 31 HIV-infected, HAV seronegative children had 100% seroconversion 4 to 8 weeks after a standard 2-dose HAV vaccination. 13 The PACTG1008 study, conducted in the United States, showed that 97% (146/151) of HIV-infected HAV seronegative children receiving ART had seroconversion after a 2-dose HAV vaccination. 10 These 2 studies and our study demonstrate the similar rates of seroconversion to HAV vaccination in developed and developing countries with different prevalence rates of HAV infection in the general population. However, a recent US study 14 demonstrated a lower seroconversion rate (84.5%, 71/84) in HIV-infected children after receiving a standard 2-dose vaccination. This might be due to poorer virologic status of children at enrollment (42.3% did not have viral suppression) compared with other studies. Moreover, the duration between the completion of 2-dose HAV vaccination and the time of antibody measurement was longer (median: 41.8 weeks, range: 4.6 -132.7 weeks) compared with other studies. 10, 13 It should also be noted that in the PACTG1006 study, the vaccine response rate was only 60% (12/20) in severely immune suppressed HIV-infected children (median CD4 cell percentage was 7%) after receiving a 3-dose HAV vaccination in the first 6 months after ART initiation. 15 Unlike healthy children who responded well with high antibody titers after a 2-dose HAV vaccination (GMTs of 4008 and 8537 mIU/mL), 16, 17 HIV-infected children usually had lower antibody titers. In our study, the mean GMT after a 2-dose HAV vaccination was 520.95 mIU/mL. Weinberg et al reported a median antibody titer of 320 mIU/mL 8 weeks after a 2-dose HAV vaccination. 10 This may imply that the protective antibody response in HIV-infected children may not be maintained for a long period of time as that in healthy children and adults whose protective antibody response could last for more than 20 years. 18 By univariate analysis, we found that younger age, higher CD4 lymphocyte count, and undetectable plasma HIV RNA level at enrollment were determining factors of high HAV antibody response after vaccination. In the multivariate analysis, we found that female gender, age Ͻ12 years and higher CD4 lymphocyte count at enrollment were predicting factors for high HAV antibody response. These findings are similar to those of other studies. 10, 14, 19 There are some limitations of our study. First, our study population already had been on ART for Ͼ1 year. Almost all of them had viral suppression. We cannot determine the best duration of ART before giving primary HAV vaccination. Second, we did not have HIV-infected children who had not yet needed ART, which might be another appropriate time to give primary HAV vaccination. Finally, it required a long-term follow-up to see the decay rate of HAV antibody levels. However on the basis of our findings, we recommend that HIV-infected children who are on ART should receive a primary 2-dose HAV vaccination when their CD4 lymphocyte counts reach normal range. Alternatively, if the children are diagnosed early they should be given a primary 2-dose HAV vaccination while their CD4 lymphocyte counts are still in the normal range, as recommended by the United States ACIP. nteroviruses produce a wide spectrum of disorders including minor febrile illness, hand-, foot-, and mouth diseases, aseptic meningitis, encephalitis, neonatal sepsis-like disease, myocarditis, hepatitis, and poliomyelitis-like illness. Enterovirus-associated aseptic meningitis is usually a benign, self-limited illness that mainly affects children. It often occurs as outbreaks, with both epidemic and endemic patterns of disease. The predominant serotypes cycle with varying periodicity within communities depending on the availability of susceptible hosts. The most frequent causal agents are Coxsackievirus B types 1-5 and echovirus types 4, 6, 9, 11, 16, and 30. Different serotype of enteroviruses circulated in Taiwan yearly. Some of them pose neurologic threat to the children, especially the enterovirus 71 (EV71). 1 In addition to EV71, other serotype of enterovirus infection may also associate with the neurologic complication, such as aseptic meningitis, meningoencephalitis, and poliomyelitis-like syndrome.
Echovirus 18 (E18) belongs to the family Picornaviridae, human Enterovirus B. The first outbreak of E18 aseptic meningitis was from North Carolina in 1972.
2 E18 had not been reported to produce aseptic meningitis in Taiwan before the current outbreak. In the past, nationwide aseptic meningitis outbreaks in Taiwan have been associated with increased circulation of other specific enterovirus serotypes, particularly coxsackievirus B, 3 echovirus 6 (E6) and 30 (E30). 4 This report describes the epidemiologic, clinical, and laboratory characteristics of 80 E18-infected children during 2006.
METHODS

Patient Enrollment and Case Definition.
The medical records of 80 consecutive patients (age, Ͻ18 years) with confirmed E18 infections were retrospectively reviewed. All patients were managed at National Cheng Kung University Hospital between January and August 2006. Acute E18 illness was defined as the isolation of E18 from a throat or rectal/stool swab or cerebrospinal fluid (CSF) of children with signs and symptoms compatible with an enterovirus infection, but negative bacterial culture. Aseptic meningitis was defined as clinical signs of nuchal rigidity, headache, and lethargy combined with isolation of the virus from the CSF or another site, regardless of the presence of CSF pleocytosis (Ͼ5 cells/mm 3 ). Virus Isolation, Detection, and Identification. The specimens were inoculated within 24 hours on stationary monolayers of rhabdomyosarcoma cells, A549 cells, green monkey kidney cells, and Vero cells. Echovirus strains were typed using Lim and Benyesh-Melnick pools and/or by immunofluorescence with monoclonal antibodies. Statistical Analysis. All analyses were performed using the SPSS for Windows (version 11.5; SPSS). A difference with P Ͻ 0.05 was considered to be significant.
